将HCV病毒血症供肾移植给HCV未感染受者的成本效益
该研究采用马尔可夫状态转换决策模型,评估将HCV病毒血症供肾移植给HCV未感染受者并治疗HCV的成本效益。基于美国血液透析等待移植患者,结果显示该策略比等待HCV未暴露供肾更有效且成本更低,主要归因于等待时间缩短、透析死亡风险降低以及直接抗病毒药物高效。敏感性分析中该策略仍具成本效益,除非HCV病毒血症供肾等待时间超过3.1年(基础值1.56年)。
要点
- 将HCV病毒血症供肾移植给HCV未感染受者并治疗HCV,可增加质量调整寿命年并降低成本。
- 该策略优于等待HCV未暴露供肾,除非前者等待时间超过3.1年。
- 直接抗病毒药物的高效性是支持该策略成本效益的关键因素。
核心结论
- 将HCV病毒血症供肾移植给HCV未感染受者并治疗HCV,相比等待HCV未暴露供肾,增加质量调整寿命年并降低费用。
研究设计与样本
- 马尔可夫状态转换决策模型,数据来源包括Medline检索、相关英文文献、移植受者科学登记系统及美国肾脏数据系统。
- 研究对象为美国接受维持性血液透析并等待肾移植的患者。
主要发现
- 基础分析中,HCV病毒血症供肾移植比HCV未暴露供肾移植更有效且成本更低。
- 敏感性分析中,多个模型参数下HCV病毒血症供肾移植仍为首选策略。
- 该策略保持成本效益,除非HCV病毒血症供肾等待时间超过3.1年(基础值1.56年)。
关键数值与推荐
- 效果以质量调整寿命年衡量,成本以2018年美元衡量。
- 基础案例中HCV病毒血症供肾等待时间为1.56年。
- 当HCV病毒血症供肾等待时间超过3.1年时,该策略不再具有成本效益。
临床怎么用
- 对于等待肾移植的HCV未感染透析患者,可考虑接受HCV病毒血症供肾并接受HCV治疗,以缩短等待时间并改善结局。
局限性
- 愿意接受HCV病毒血症供肾患者的等待时间估计基于已接受该类移植患者的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Less than 4% of patients with kidney failure receive kidney transplants. Although discard rates of hepatitis C virus (HCV)-viremic kidneys are declining, ~39% of HCV-viremic kidneys donated between 2018 and 2019 were discarded. Highly effective antiviral agents are now available to treat chronic HCV infection. Thus, our objective was to examine the cost-effectiveness of transplanting kidneys from HCV-viremic donors into HCV-uninfected recipients. STUDY DESIGN: Markov state transition decision model. Data sources include Medline search results, bibliographies from relevant English language articles, Scientific Registry of Transplant Recipients, and the US Renal Data System. SETTING & POPULATION: US patients receiving maintenance hemodialysis who are on kidney transplant waiting lists. INTERVENTION(S): Transplantation with an HCV-unexposed kidney versus transplantation with an HCV-viremic kidney and HCV treatment. OUTCOMES: Effectiveness measured in quality-adjusted life-years and costs measured in 2018 US dollars. MODEL, PERSPECTIVE, AND TIMEFRAME: We used a health care system perspective with a lifelong time horizon. RESULTS: In the base-case analysis, transplantation with an HCV-viremic kidney was more effective and less costly than transplantation with an HCV-unexposed kidney because of the longer waiting times for HCV-unexposed kidneys, the substantial excess mortality risk while receiving dialysis, and the high efficacy of direct-acting antiviral agents for HCV infection. Transplantation with an HCV-viremic kidney was also preferred in sensitivity analyses of multiple model parameters. The strategy remained cost-effective unless waiting list time for an HCV-viremic kidney exceeded 3.1 years compared with the base-case value of 1.56 year. LIMITATIONS: Estimates of waiting times for patients willing to accept an HCV-viremic kidney were based on data for patients who received HCV-viremic kidney transplants. CONCLUSIONS: Transplanting kidneys from HCV-viremic donors into HCV-uninfected recipients increased quality-adjusted life expectancy and reduced costs compared with a strategy of transplanting kidneys from HCV-unexposed donors.
引用
- Eckman MH, Woodle ES, Thakar CV, et al. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. Am J Kidney Dis. 2020. PMID: 32081494. doi:10.1053/j.ajkd.2019.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。